Phase 3 trial of BGB-A317.

Trial Profile

Phase 3 trial of BGB-A317.

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 03 Oct 2017 New trial record
    • 28 Sep 2017 According to a BeiGene, Ltd. media release, this trial is expected to initiate in the fourth quarter of 2017 or first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top